# Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Study · id `cardio:ct-nct07223593` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07223593](<https://clinicaltrials.gov/study/NCT07223593>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07223593

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1205 participants.

## Technical summary

Registry record NCT07223593. Randomized; double masking; primary purpose treatment. Start 2025-10-31 (actual); primary completion 2028-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1205 participants (planned count; ClinicalTrials.gov record NCT07223593, source copy `cardio:ctgov-nct07223593-2026-11-04`, retrieved 2026-11-18)
- Started: 2025-10-31 (actual) (ClinicalTrials.gov record NCT07223593, source copy `cardio:ctgov-nct07223593-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT07223593, source copy `cardio:ctgov-nct07223593-2026-11-04`, retrieved 2026-11-18)
- Completion: 2028-06 (anticipated) (ClinicalTrials.gov record NCT07223593, source copy `cardio:ctgov-nct07223593-2026-11-04`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Brazil; Canada; China; France; Greece; India; Israel; Japan; Netherlands; Poland; Puerto Rico; Slovakia; South Korea; Taiwan; United Kingdom (ClinicalTrials.gov record NCT07223593, source copy `cardio:ctgov-nct07223593-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07223593-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- Acronym: ATTAIN-PAD
- Condition: Peripheral Arterial Disease
- Intervention (Drug): Orforglipron
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 87cde6adb2337b49bc709f81ca8391f3f8b336fc1ab7ddac55ec3f4df4cacc28
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
